NORTH AMERICA EPIGENOMICS MARKET 2018-2026
North America Epigenomics Market by Product (Reagents, Kits, Instruments, Enzymes, Services) by Technology (Dna Methylation, Histone Methylation & Acetylation, Microrna Modification) by Application (Oncology, Non-oncology) by Application Area (Diagnosis, Drug Discovery, Therapy Optimization, Prognosis) by Segment (Epigenetic Diagnosis(Cancer, Neuro, Inflammatory & Autoimmune Disease, R&d, Personalized Medicine, Neurological Disorders, Cvd, Others), Epigenetic Therapies(Biomarkers, Noncoding Rnas, Mirnas, Chromatin Remodeling)) by Geography.
North America epigenomics market is anticipated to rise at a CAGR of 17.51% during the forecast period of 2018-2026. The presence of a large number of biotech and pharmaceutical manufacturers gives an edge to this region as compared to other regional markets.
The report presents a detailed analysis of geographies such as the US and Canada for the North America epigenomics market. The US has witnessed a high prevalence of cancer in the last few years. Other disorders like cardiovascular and neurological diseases have also seen a considerable rise in this region. As a combined result of all these factors, the epigenomics market demand has witnessed a significant rise in this region.
Leading market players in this region include Merck Sharp & Dohme, Roche Holding Ag, Glaxosmithkline, Naturewise Biotech & Medicals Corp, Johnson & Johnson, Abbott Laboratories, Rubicon Genomics, Epigentek, Astellas Pharmaceuticals, Epigenomics Ag, Agilent Technologies, Affymetrix, Novartis Pharma Ag, Bayer Ag, Orchid Chemicals & Pharmaceuticals Limited, Celgene Corp, and Illumina Inc.
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
- RESEARCH METHODOLOGY
- SOURCES OF DATA
- SECONDARY DATA
- PRIMARY DATA
- TOP-DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- SOURCES OF DATA
- EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
- ASIA PACIFIC IS ANTICIPATED TO BE THE MOST DYNAMIC REGIONAL MARKET
- REAGENTS FORMS A MAJOR PART OF EPIGENOMIC MARKET BY PRODUCT
- EPIGENETICS DIAGNOSIS IS A MAJOR PART OF EPIGENOMIC MARKET, AND PERSONALIZED MEDICINES IS SHOWING A DYNAMIC GROWTH
- ONCOLOGY IS THE PRIMARY APPLICATION WHILE NON-ONCOLOGY IS SHOWING A BETTER GROWTH
- MARKET DYNAMICS
- MARKET DEFINITION & SCOPE
- MARKET DRIVERS
- ADVANCEMENT IN THE PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES
- RISE IN THE AGEING POPULATION
- DECLINE IN THE SEQUENCING COSTS AND TIME
- ESCALATION IN FUNDING FOR RESEARCH & DEVELOPMENT
- NEED FOR BETTER CANCER THERAPIES
- GROWTH IN PERSONALIZED MEDICINE
- INCREASING IMPORTANCE OF EPIGENETIC TECHNOLOGY
- MARKET RESTRAINTS
- INEFFICIENCY IN IDENTIFICATION AND VALIDATION OF BIOMARKER
- PRESENCE OF COMPLEX REGULATORY FRAMEWORK
- LACK OF REIMBURSEMENT PROVISION IN INSURANCE FOR EPIGENOMIC
- MARKET OPPORTUNITIES
- INCREASING AWARENESS ABOUT EPIGENOMIC
- ADVANCEMENT OF POTENTIAL IN EMERGING MARKETS
- EXPANDING APPLICATIONS OF EPIGENETICS IN PERSONALIZED MEDICINE AND TARGETED THERAPY
- USE OF EPIGENOMIC IN NON-ONCOLOGY APPLICATIONS
- MARKET CHALLENGES
- SCARCITY OF TRAINED PROFESSIONALS
- HIGH COST OF INSTRUMENTS AND CONSUMABLES
- MARKET BY PRODUCT
- REAGENTS
- KITS
- INSTRUMENTS
- ENZYMES
- SERVICES
- MARKET BY TECHNOLOGY
- DNA METHYLATION
- HISTONE METHYLATION & ACETYLATION
- MICRORNA MODIFICATION
- MARKET BY APPLICATION
- ONCOLOGY
- DNA METHYLTRANSFERASE INHIBITORS
- HISTONE DEACETYLASE INHIBITORS
- NON-ONCOLOGY
- ONCOLOGY
- MARKET BY APPLICATION AREA
- DIAGNOSIS
- DRUG DISCOVERY
- THERAPY OPTIMIZATION
- PROGNOSIS
- MARKET BY SEGMENT
- EPIGENETIC DIAGNOSIS
- CANCER
- NEURO
- MENTAL RETARDATION
- ALZHEIMER’S DISEASE
- DEPRESSION
- OTHER
- CARDIOVASCULAR
- VASCULAR DISEASE
- HEART FAILURE
- OTHERS
- INFLAMMATORY & AUTOIMMUNE DISEASE
- RHEUMATOID ARTHRITIS
- DIABETES
- LUPUS
- MULTIPLE SCLEROSIS
- INFLAMMATORY BOWEL DISEASES
- R&D
- DNA METHYLATION IN CANCER DETECTION
- IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION
- MECHANISMS OF EPIGENETIC GENE SILENCING
- PERSONALIZED MEDICINE
- CANCER TREATMENT
- LUNG CANCER
- SOLID CANCERS
- GASTRIC CANCER
- HAEMATOLOGICAL CANCERS
- OTHERS
- NEUROLOGICAL DISORDERS
- MENTAL RETARDATION
- HUNTINGTON’S DISEASE
- PARKINSON’S DISEASE
- ALZHEIMER’S DISEASE
- DEPRESSION
- CVD
- OTHERS
- RHEUMATOID ARTHRITIS
- DIABETES
- MYELODYSPLASTIC SYNDROMES
- MULTIPLE SCLEROSIS
- OBESITY
- INFLAMMATORY BOWEL DISEASES
- LUPUS
- OTHER
- CANCER TREATMENT
- EPIGENETIC THERAPIES
- BIOMARKERS
- DNA METHYLATION FOR CANCER DETECTION
- HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION
- HISTONE METHYLATION
- HISTONE ACETYLATION
- NONCODING RNAS
- MIRNAS
- CHROMATIN REMODELING
- BIOMARKERS
- EPIGENETIC DIAGNOSIS
- KEY ANALYTICS
- PORTER’S FIVE FORCE MODEL
- THREAT OF NEW ENTRANTS
- THREAT OF SUBSTITUTE
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF BUYERS
- THREAT OF COMPETITIVE RIVALRY
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- PORTER’S FIVE FORCE MODEL
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- UNITED STATES
- CANADA
- NORTH AMERICA
- COMPANY PROFILES
- ABBOTT LABORATORIES
- AFFYMETRIX
- AGILENT TECHNOLOGIES
- ASTELLAS PHARMACEUTICALS
- BAYER AG
- BIO VISION
- CELGENE CORP.
- EPIGENOMICS AG
- GLAXOSMITHKLINE
- ILLUMINA INC.
- JOHNSON & JOHNSON
- MERCK SHARP & DOHME
- NATUREWISE BIOTECH & MEDICALS CORP.
- NOVARTIS PHARMA AG
- ORCHID CHEMICALS & PHARMACEUTICALS LIMITED
- TBG DIAGNOSTICS LIMITED
- RUBICON GENOMICS
- ROCHE HOLDING AG
LIST OF TABLES
TABLE 1 NORTH AMERICA EPIGENOMIC MARKET, BY COUNTRY, 2018-2026, (IN $ TEN THOUSAND)
TABLE 2 NORTH AMERICA EPIGENOMIC MARKET, BY PRODUCT, 2018-2026, (IN $ TEN THOUSAND)
TABLE 3 NORTH AMERICA EPIGENOMIC MARKET, BY TECHNOLOGY, 2018-2026, (IN $ TEN THOUSAND)
TABLE 4 NORTH AMERICA EPIGENOMIC MARKET, BY APPLICATION, 2018-2026, (IN $ TEN THOUSAND)
TABLE 5 NORTH AMERICA EPIGENOMIC MARKET, BY APPLICATION AREA, 2018-2026, (IN $ TEN THOUSAND)
TABLE 6 NORTH AMERICA EPIGENOMIC MARKET, BY SEGMENT, 2018-2026, (IN $ TEN THOUSAND)
TABLE 7 NORTH AMERICA EPIGENOMIC MARKET, BY EPIGENETIC DIAGNOSIS, 2018-2026 (IN $ TEN THOUSAND)
TABLE 8 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY NEURO, 2018-2026, (IN $ TEN THOUSAND)
TABLE 9 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY CARDIOVASCULAR, 2018-2026, (IN $ TEN THOUSAND)
TABLE 10 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY INFLAMMATORY & AUTOIMMUNE DISEASE, 2018-2026, (IN $ TEN THOUSAND)
TABLE 11 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY R&D, 2018-2026, (IN $ TEN THOUSAND)
TABLE 12 NORTH AMERICA EPIGENOMIC MARKET, BY PERSONALIZED MEDICINE, 2018-2026, (IN $ TEN THOUSAND)
TABLE 13 NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY CANCER TREATMENT, 2018-2026, (IN $ TEN THOUSAND)
TABLE 14 NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY NEUROLOGICAL DISORDERS, 2018-2026 (IN $ TEN THOUSAND)
TABLE 15 NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY OTHERS, 2018-2026 (IN $ TEN THOUSAND)
TABLE 16 NORTH AMERICA EPIGENOMICS MARKET, BY BIOMARKERS, 2018-2026 (IN $ TEN THOUSAND)
TABLE 17 OPPORTUNITY MATRIX
TABLE 18 VENDOR LANDSCAPE
TABLE 19 NORTH AMERICA EPIGENOMIC MARKET, BY COUNTRY, 2018-2026 (IN $ TEN THOUSAND)
LIST OF FIGURES
TABLE 1 NORTH AMERICA EPIGENOMIC MARKET, BY COUNTRY, 2018-2026, (IN $ TEN THOUSAND)
TABLE 2 NORTH AMERICA EPIGENOMIC MARKET, BY PRODUCT, 2018-2026, (IN $ TEN THOUSAND)
TABLE 3 NORTH AMERICA EPIGENOMIC MARKET, BY TECHNOLOGY, 2018-2026, (IN $ TEN THOUSAND)
TABLE 4 NORTH AMERICA EPIGENOMIC MARKET, BY APPLICATION, 2018-2026, (IN $ TEN THOUSAND)
TABLE 5 NORTH AMERICA EPIGENOMIC MARKET, BY APPLICATION AREA, 2018-2026, (IN $ TEN THOUSAND)
TABLE 6 NORTH AMERICA EPIGENOMIC MARKET, BY SEGMENT, 2018-2026, (IN $ TEN THOUSAND)
TABLE 7 NORTH AMERICA EPIGENOMIC MARKET, BY EPIGENETIC DIAGNOSIS, 2018-2026 (IN $ TEN THOUSAND)
TABLE 8 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY NEURO, 2018-2026, (IN $ TEN THOUSAND)
TABLE 9 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY CARDIOVASCULAR, 2018-2026, (IN $ TEN THOUSAND)
TABLE 10 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY INFLAMMATORY & AUTOIMMUNE DISEASE, 2018-2026, (IN $ TEN THOUSAND)
TABLE 11 NORTH AMERICA EPIGENETIC DIAGNOSIS MARKET, BY R&D, 2018-2026, (IN $ TEN THOUSAND)
TABLE 12 NORTH AMERICA EPIGENOMIC MARKET, BY PERSONALIZED MEDICINE, 2018-2026, (IN $ TEN THOUSAND)
TABLE 13 NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY CANCER TREATMENT, 2018-2026, (IN $ TEN THOUSAND)
TABLE 14 NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY NEUROLOGICAL DISORDERS, 2018-2026 (IN $ TEN THOUSAND)
TABLE 15 NORTH AMERICA PERSONALIZED MEDICINE MARKET, BY OTHERS, 2018-2026 (IN $ TEN THOUSAND)
TABLE 16 NORTH AMERICA EPIGENOMICS MARKET, BY BIOMARKERS, 2018-2026 (IN $ TEN THOUSAND)
TABLE 17 OPPORTUNITY MATRIX
TABLE 18 VENDOR LANDSCAPE
TABLE 19 NORTH AMERICA EPIGENOMIC MARKET, BY COUNTRY, 2018-2026 (IN $ TEN THOUSAND)
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- UNITED STATES
- CANADA
- NORTH AMERICA
- MARKET BY PRODUCT
- REAGENTS
- KITS
- INSTRUMENTS
- ENZYMES
- SERVICES
- MARKET BY TECHNOLOGY
- DNA METHYLATION
- HISTONE METHYLATION & ACETYLATION
- MICRORNA MODIFICATION
- MARKET BY APPLICATION
- ONCOLOGY
- DNA METHYLTRANSFERASE INHIBITORS
- HISTONE DEACETYLASE INHIBITORS
- NON-ONCOLOGY
- ONCOLOGY
- MARKET BY APPLICATION AREA
- DIAGNOSIS
- DRUG DISCOVERY
- THERAPY OPTIMIZATION
- PROGNOSIS
- MARKET BY SEGMENT
- EPIGENETIC DIAGNOSIS
- CANCER
- NEURO
- MENTAL RETARDATION
- ALZHEIMER’S DISEASE
- DEPRESSION
- OTHER
- CARDIOVASCULAR
- VASCULAR DISEASE
- HEART FAILURE
- OTHERS
- INFLAMMATORY & AUTOIMMUNE DISEASE
- RHEUMATOID ARTHRITIS
- DIABETES
- LUPUS
- MULTIPLE SCLEROSIS
- INFLAMMATORY BOWEL DISEASES
- R&D
- DNA METHYLATION IN CANCER DETECTION
- IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION
- MECHANISMS OF EPIGENETIC GENE SILENCING
- PERSONALIZED MEDICINE
- CANCER TREATMENT
- LUNG CANCER
- SOLID CANCERS
- GASTRIC CANCER
- HAEMATOLOGICAL CANCERS
- OTHERS
- NEUROLOGICAL DISORDERS
- MENTAL RETARDATION
- HUNTINGTON’S DISEASE
- PARKINSON’S DISEASE
- ALZHEIMER’S DISEASE
- DEPRESSION
- CVD
- OTHERS
- RHEUMATOID ARTHRITIS
- DIABETES
- MYELODYSPLASTIC SYNDROMES
- MULTIPLE SCLEROSIS
- OBESITY
- INFLAMMATORY BOWEL DISEASES
- LUPUS
- OTHER
- CANCER TREATMENT
- EPIGENETIC THERAPIES
- BIOMARKERS
- DNA METHYLATION FOR CANCER DETECTION
- HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION
- HISTONE METHYLATION
- HISTONE ACETYLATION
- NONCODING RNAS
- MIRNAS
- CHROMATIN REMODELING
- BIOMARKERS
- EPIGENETIC DIAGNOSIS
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.